Insulet (PODD) Competitors $282.80 -5.49 (-1.90%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$282.79 -0.01 (-0.01%) As of 02/21/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PODD vs. BDX, EW, IDXX, DXCM, RMD, STE, BAX, HOLX, GMED, and MASIShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry. Insulet vs. Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom ResMed STERIS Baxter International Hologic Globus Medical Masimo Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking. Which has more volatility and risk, BDX or PODD? Becton, Dickinson and Company has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Is BDX or PODD more profitable? Insulet has a net margin of 21.22% compared to Becton, Dickinson and Company's net margin of 8.47%. Insulet's return on equity of 27.98% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Becton, Dickinson and Company8.47% 15.74% 7.29% Insulet 21.22%27.98%9.16% Do analysts rate BDX or PODD? Becton, Dickinson and Company currently has a consensus target price of $278.29, suggesting a potential upside of 22.30%. Insulet has a consensus target price of $289.06, suggesting a potential upside of 2.21%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Becton, Dickinson and Company 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Insulet 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81 Do insiders & institutionals have more ownership in BDX or PODD? 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor BDX or PODD? In the previous week, Becton, Dickinson and Company had 15 more articles in the media than Insulet. MarketBeat recorded 48 mentions for Becton, Dickinson and Company and 33 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.51 beat Insulet's score of 0.96 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 42 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insulet 13 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, BDX or PODD? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBecton, Dickinson and Company$20.18B3.24$1.71B$6.0237.80Insulet$1.70B11.69$206.30M$5.8448.42 Does the MarketBeat Community believe in BDX or PODD? Insulet received 133 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 66.39% of users gave Insulet an outperform vote while only 62.43% of users gave Becton, Dickinson and Company an outperform vote. CompanyUnderperformOutperformBecton, Dickinson and CompanyOutperform Votes60062.43% Underperform Votes36137.57% InsuletOutperform Votes73366.39% Underperform Votes37133.61% SummaryInsulet beats Becton, Dickinson and Company on 10 of the 18 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.84B$4.59B$5.80B$8.94BDividend YieldN/A39.91%4.78%3.85%P/E Ratio48.4230.6126.4118.84Price / Sales11.6949.73450.1476.68Price / Cash74.7551.2344.0437.47Price / Book26.966.577.634.64Net Income$206.30M$90.13M$3.18B$245.69M7 Day Performance0.80%-2.53%-1.82%-2.59%1 Month Performance2.43%-2.42%0.22%-2.30%1 Year Performance46.92%15.15%17.25%13.71% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.3609 of 5 stars$282.80-1.9%$289.06+2.2%+46.9%$20.22B$1.98B48.423,000Earnings ReportAnalyst ForecastNews CoverageGap DownHigh Trading VolumeBDXBecton, Dickinson and Company4.9252 of 5 stars$224.89-0.1%$278.29+23.7%-7.3%$65.22B$20.18B37.3674,000Positive NewsEWEdwards Lifesciences4.4114 of 5 stars$76.23+0.3%$79.95+4.9%-15.5%$44.96B$6.00B11.0019,800Positive NewsIDXXIDEXX Laboratories4.5297 of 5 stars$444.53-3.3%$533.75+20.1%-18.4%$36.40B$3.90B41.6611,000Positive NewsDXCMDexCom4.7438 of 5 stars$89.07+5.9%$99.06+11.2%-23.7%$34.79B$3.62B53.349,600Positive NewsHigh Trading VolumeRMDResMed4.3687 of 5 stars$232.93-2.7%$244.73+5.1%+28.5%$34.21B$4.69B27.509,980Analyst RevisionPositive NewsSTESTERIS4.7468 of 5 stars$219.54+0.1%$258.75+17.9%-5.4%$21.57B$5.40B46.6118,179Positive NewsBAXBaxter International4.1993 of 5 stars$30.83+0.7%$39.44+27.9%-19.8%$15.74B$14.81B154.1660,000Earnings ReportAnalyst ForecastNews CoverageHOLXHologic4.934 of 5 stars$63.24-0.6%$85.77+35.6%-15.0%$14.27B$4.03B19.957,063GMEDGlobus Medical4.8338 of 5 stars$83.99-0.2%$96.91+15.4%+46.3%$11.44B$1.57B125.365,000Earnings ReportAnalyst ForecastNews CoverageMASIMasimo3.7241 of 5 stars$181.31+1.0%$191.40+5.6%+28.7%$9.71B$2.05B125.045,200Analyst RevisionPositive News Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives IDEXX Laboratories Alternatives DexCom Alternatives ResMed Alternatives STERIS Alternatives Baxter International Alternatives Hologic Alternatives Globus Medical Alternatives Masimo Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PODD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.